D.E. Shaw & Co
DGX icon

D.E. Shaw & Co’s Quest Diagnostics DGX Stock Holding History

D.E. Shaw & Co’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-4,100
Closed -$469K – 3961
2020
Q3 		$469K Hold
4,100
– – ﹤0.01% 3260
2020
Q2 		$467K Buy
+4,100
New +$435K ﹤0.01% 3410
2017
Q4 		– Sell
-5,300
Closed -$496K – 3591
2017
Q3 		$496K Buy
+5,300
New +$563K ﹤0.01% 2912

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

D.E. Shaw & Co's DGX Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Quest Diagnostics (DGX) stake by 55% in Q1 2026, selling an estimated $35.2M and leaving 147,727 shares worth $29M. The position accounts for 0.02% of the portfolio, ranked #925.

D.E. Shaw & Co first reported a position in DGX in Q4 2013 and has held it in 43 quarters since. The position peaked at $66.5M in Q4 2021. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • D.E. Shaw & Co held 147,727 shares of Quest Diagnostics worth $29M as of Q1 2026.
  • D.E. Shaw & Co sold 181,007 Quest Diagnostics shares in Q1 2026, an estimated $35.2M.
  • Quest Diagnostics made up 0.02% of D.E. Shaw & Co's portfolio in Q1 2026, its #925 holding.
  • D.E. Shaw & Co first reported a position in Quest Diagnostics in Q4 2013 and has held it in 43 quarters since.
  • D.E. Shaw & Co's Quest Diagnostics position peaked at $66.5M in Q4 2021.
  • 1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.